The HCV protease inhibitors (Incivek and Victrelis) have been out for less than a year. These drugs raise new issues, particularly the risk of developing resistance. Interactions with other drugs and supplements are a new problem that was not a major concern with combination peginterferon and ribavirin. These new drugs increase the risk of certain [...]
